semaglutide vision changes Long-term use of and risk of diabetic retinopathy progression Possible Link Between GLP-1 RA

The ongoing second part of the study is evaluating MariTide beyond 52 weeks, looking at additional weight loss with continued treatment, weight maintenance using less frequent or lower dosing and durability of weight loss following treatment discontinuation

Los CMS recopilarn y compartirn los datos del uso de GLP-1 del programa puente con las aseguradoras de la Parte D y los usar para decidir despus si el programa piloto se llevar a cabo

The FDA also approved the first oral GLP-1 for weight loss (oral Wegovy) in December 2025, potentially reshaping pharmacy benefit dynamics ( [8] )

Offer ends 8/31/26

Timing the transition matters too